Compugen Ltd.
A clinical-stage company developing cancer immunotherapies using an AI platform.
CGEN | TA
Overview
Corporate Details
- ISIN(s):
- IL0010852080
- LEI:
- Country:
- Israel
- Address:
- 26 Harokmim St., Bldg D, 5885849 Holon
- Website:
- https://www.cgen.com/
Description
Compugen Ltd. is a clinical-stage therapeutic discovery and development company specializing in cancer immunotherapy. A pioneer in its field, the company leverages a proprietary, broadly applicable, and predictive AI-powered computational discovery platform to identify novel drug targets. Its primary focus is on developing innovative, first-in-class therapeutics designed to modulate the tumor microenvironment and enhance anti-tumor immune responses. Compugen's mission is to advance its pipeline of drug candidates to address patient populations unresponsive to current immunotherapy treatments.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-02-26 15:00 |
Compugen Enhances its AI/ML Predictive Computational Discovery Platform, Unigen…
|
English | 36.3 KB | ||
| 2025-02-18 15:00 |
Compugen to Release Fourth Quarter and Full Year 2024 Financial Results on Tues…
|
English | 91.6 KB | ||
| 2025-02-18 15:00 |
Compugen to Release Fourth Quarter and Full Year 2024 Financial Results on Tues…
|
English | 36.3 KB | ||
| 2025-02-15 19:45 |
Form SCHEDULE 13G/A 1- BRISTOL MYERS SQUIBB CO
|
English | 195.6 KB | ||
| 2025-02-15 19:45 |
Form SCHEDULE 13G/A 1- BRISTOL MYERS SQUIBB CO
|
English | 36.2 KB | ||
| 2025-02-04 15:00 |
Compugen to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Con…
|
English | 92.0 KB | ||
| 2025-02-04 15:00 |
Compugen to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Con…
|
English | 36.3 KB | ||
| 2025-01-08 14:59 |
Compugen Announces First Patient Dosed in Phase 1 Clinical Trial to Evaluate CO…
|
English | 466.8 KB | ||
| 2025-01-08 14:59 |
Compugen Announces First Patient Dosed in Phase 1 Clinical Trial to Evaluate CO…
|
English | 36.4 KB | ||
| 2024-11-27 14:59 |
Compugen Expands its Intellectual Property Portfolio with New U.S. Patent Cover…
|
English | 425.0 KB | ||
| 2024-11-27 14:59 |
Compugen Expands its Intellectual Property Portfolio with New U.S. Patent Cover…
|
English | 36.4 KB | ||
| 2024-11-12 14:59 |
Compugen Reports Third Quarter 2023 Results
|
English | 437.9 KB | ||
| 2024-11-12 14:59 |
Compugen Reports Third Quarter 2023 Results
|
English | 36.2 KB | ||
| 2024-11-11 14:59 |
Compugen to Participate in Stifel 2024 Healthcare Conference
|
English | 90.2 KB | ||
| 2024-11-11 14:59 |
Compugen to Participate in Stifel 2024 Healthcare Conference
|
English | 36.3 KB |
Automate Your Workflow. Get a real-time feed of all Compugen Ltd. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Compugen Ltd.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Compugen Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
